Granci et al. [28] studied the TRAIL receptors TRAIL-R 1, -2, -3 and -4 expression by immunohistochemistry in metastatic stage IV CRC and found that concomitant low/mediumTRAIL-R1 and high TRAIL-R3 expression in primary CRC is significantly associated with a poor response to 5-FU-based first-line chemotherapy and with a shorter progression-free survival. Here, TNFSF10 is linked to colorectal carcinoma.